By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Like many of you,...

Another day, another “restructuring” – there’s been a flurry of press releases recently using phrases like “exploring strategic alternatives”, “extending the cash runway”, and...

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC Our company recently launched out of stealth...

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is...

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry,...

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the...

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing...

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small...

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC. In December 2019, I was in London meeting...

By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC. No, your...

By Deanna M. Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC One of the most common questions I get...

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced,...